CBL is an E3 ubiquitin ligase that targets both active β-catenin and FLT3 (fms related receptor tyrosine kinase 3): two factors important for tumor-induced angiogenesis which have also been implicated in AML (Lyle et al., 2019). This evidence concerns the gene FLT3 and acute myeloid leukemia.